DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) commences share repurchases on April 30, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on April 1, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 200 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 34.51 per share.

The purpose of the program is sustainable and stable development in the future and the recognition of the company's value, in order to effectively protect the interests of all shareholders, enhance public investors' confidence in the company, and promote the reasonable return of the company's stock value. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The repurchases will be made from company's own funds.

The program will be valid till 12 months from the date of approval by shareholders.